导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.86% | 3560/4773 |
| 近一周 | -3.66% | 4431/5462 |
| 近一月 | -0.14% | 746/5421 |
| 近一季 | -1.42% | 995/5209 |
| 近半年 | -14.44% | 3911/4920 |
| 近一年 | -9.16% | 3307/4366 |
| 近两年 | 20.34% | 2642/2954 |
| 近三年 | 21.02% | 1432/2253 |
| 成立以来 | 31.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.97% 820/4961 |
-16.87% 4749/5312 |
- - |
- - |
| 2025 | 16.82% 2409/4813 |
0.98% 1724/3635 |
6.27% 471/4076 |
8.58% 3406/4524 |
0.26% 2098/4813 |
| 2024 | 11.78% 1298/3463 |
1.60% 872/2808 |
14.61% 9/3014 |
-1.89% 2961/3129 |
-2.15% 1974/3463 |
| 2023 | 2.83% 302/2656 |
3.62% 1160/2280 |
-2.11% 559/2385 |
-0.23% 408/2515 |
1.61% 80/2655 |
| 2022 | -11.99% 267/2207 |
-6.35% 214/1919 |
2.55% 1287/2016 |
-17.44% 1595/2113 |
10.99% 158/2208 |
| 2021 | 3.66% 605/1822 |
11.88% 21/1255 |
8.20% 643/1330 |
-8.16% 1108/1466 |
-6.76% 1550/1822 |
| 2020 | -1.12% 950/1250 |
-18.90% 1006/1028 |
7.25% 845/1067 |
6.39% 844/1164 |
6.84% 740/1184 |
| 2019 | 13.96% 702/1092 |
10.17% 721/739 |
-4.90% 441/788 |
-2.42% 699/850 |
11.47% 57/918 |
| 2018 | -13.35% 87/834 |
- - |
3.97% 14/631 |
-3.44% 321/660 |
-8.73% 107/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 民生加银港股通高股息C VS. 长安沪深300非周期A(740101) |